MedTrace Logo

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

NCT05776173 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-06-14

No results posted yet for this study

Summary

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Conditions

  • β-thalassemia Major

Interventions

GENETIC

BD211

Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Shanghai BDgene Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Sujiang Zhang, M.D. · Ruijin Hospital, Shanghai, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2026-03-31
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05776173 on ClinicalTrials.gov